New diabetes pill shows promise in Real-World study

NCT ID NCT05230589

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday clinical practice in Saudi Arabia. Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months in 194 participants. The goal was to see if the pill helps lower blood sugar and support weight loss outside of controlled trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this could confirm that oral semaglutide is effective for managing blood sugar and weight in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only included people in Saudi Arabia, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Master Centre for Saudi

Riyadh, 3542, Saudi Arabia
Specialized Medical Cente

Riyadh, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.